Gaborit B, Julla JB, Besbes S, et al. - In this AngioSafe type 2 diabetes (T2D) study, researchers determined the role of glucagon-like peptide 1 receptor agonists (GLP-1RA) in angiogenesis utilizing clinical and preclinical models. According to results,10% showed severe DR in the cohort of 3,154 T2D individuals. In multivariate analysis, gender, duration of disease, glycated hemoglobin, micro- and macroangiopathy, insulin therapy and hypertension remained strongly linked to severe DR, on the other hand, no connection was observed with GLP-1RA exposure. In addition, there was no impact of liraglutide on hematopoietic progenitor cells, and angio-miRNAs. The AngioSafe T2D studies include experimental and clinical evidence demonstrating no impact of GLP-1RA on angiogenesis and no correlation between GLP-1 exposure and severe DR.